De-identification and pseudo-anonymization are two commonly used techniques for protecting personal information in real world evidence (RWE) studies.
De-identification involves removing or obscuring any personal identifiers, such as names, addresses, and social security numbers, from a dataset. The goal is to make it impossible to identify individuals in the dataset. However, de-identified data can still potentially be re-identified if combined with other data sources or through statistical analysis.
Pseudo-anonymization involves replacing personal identifiers with a unique identifier, or code, that cannot be traced back to the individual without access to a separate database. This technique provides an additional layer of protection as the original personal identifiers are not included in the dataset. However, there is still a risk that individuals can be re-identified if the codes are compromised or if the separate database is breached.
In the context of RWE, both de-identification and pseudo-anonymization can be effective in protecting personal information. The choice of technique will depend on the level of risk associated with re-identification and the specific requirements of the study. For example, if the dataset contains sensitive information or the risk of re-identification is high, pseudo-anonymization may be preferred. If the risk of re-identification is low and the dataset does not contain sensitive information, de-identification may be sufficient.
It is important to note that neither de-identification nor pseudo-anonymization can guarantee complete protection of personal information. Additional measures, such as access controls and data use agreements, may be necessary to further reduce the risk of re-identification and protect the privacy of individuals in RWE studies.
Share this story...
Real World Evidence (RWE) 101 – Patient Retention
RWE 101 - Patient Retention Long-term Real-World Evidence (RWE) studies face significant challenges when it comes to patient retention, for several reasons:[1] Time Commitment: Participants in RWE studies are [...]
Real World Evidence (RWE) 101 – Patient Recruitment
RWE 101 - Patient Recruitment Real-world evidence (RWE) is health care information derived from real-world data (RWD). It can be generated through various study designs or analyses, including pragmatic [...]
Real World Evidence (RWE) 101 – HARPER
RWE 101 - HARPER Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or [...]
Real World Evidence (RWE) 101 – STaRT-RWE
RWE 101 - STaRT-RWE START-RWE (Structured Template for Planning and Reporting on the Implementation of Real World Evidence Studies) was developed to address the need for improved transparency and [...]
Real World Evidence (RWE) 101 – Protocol Design and ISPE GPP
RWE 101 - Protocol Design and ISPE GPP The International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) are a set of best practices for the conduct [...]
Real World Evidence (RWE) 101 – Protocol Design and Scientific Best Practices
RWE 101 - Protocol Design and Scientific Best Practices Designing a robust Real-World Evidence (RWE) study is crucial for generating reliable and valid insights that are acceptable to regulators. [...]







